Gözde YAZİCİ, Hamit BAŞARAN, İbrahim GÜLLÜ, Mustafa CENGİZ, Gökhan ÖZYİĞİT, Yurday ÖZDEMİR, Nilda SÜSLÜ

Outcome of Elderly Nasopharyngeal Carcinoma Patients: A Single Center Study

Objective: This study aimed to assess the efficiency of radiotherapy and evaluate its outcomes for elderly (>65 years) patients who have undergone treatment for nasopharyngeal carcinoma (NPC). Methods: Forty-five (male, 35; female, 10) elderly patients with a diagnosis of undifferentiated NPC who were treated at our institution between 1994 and 2012 were retrospectively evaluated. The primary endpoint was the relationship between the patients’ characteristics and overall survival (OS); progression-free survival (PFS), locoregional progression-free survival (LRPFS), and toxicity analysis were the secondary endpoints. Results: The patients had a median age of 74.2 years. At a median follow-up period of 64 months, the median OS, PFS, and LR-PFS were 45 (95% confidence interval [CI]: 5.887-84.113), 34 (95% CI: 0.0-70.504), and 45 (95% CI: 20.092-69908) months, respectively. The 2-, 3-, and 5-year OS rates were 61.5%, 53.1%, and 50.0%, respectively, and the 2-, 3-, and 5-year PFS rates were 57.6%, 46.8%, and 43.7%, respectively. Patients with T stage (T3-T4 vs.T1–T2) or N stage (N0–1 vs. N2) had significantly shorter OS (p

PDF

___

Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365: 2041-54.
Wei KR, Xu Y, et al. Histopathological classification of nasopharyngeal carcinoma. Asian Pac J Cancer Prev 2011; 12: 1141-7.
Chan AT. Nasopharyngeal carcinoma. Ann Oncol 2010; 21: i308-i312.
Wei KR, Xu Y, et al. Histopathological classification of nasopharyngeal carcinoma. Asian Pac J Cancer Prev 2011; 12: 1141-7.
Jian He, Ping Wu, et al. Chemoradiotherapy enhanced the efficacy of radiotherapy in nasopharyngeal carcinoma patients: a network meta-analysis Oncotarget 2017; 8: 39782-94.
Lin JC, Jan JS, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003; 21: 631-7.
Sze HC, Ng WT, Chan OSH, Shum TCY, Chan LLK, Lee AWM, et al. Radical radiotherapy for nasopharengeal carcinoma in elderly patients: the importance of co-morbidity assessment. Oral Oncol 2012; 48(2): 162-7.
Zhang L, Zhao C, Hong MH, Liu Q, Zhanget Y, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer 2010; 10: 558.
Lee N, Xia P, Sultanem K, Poon I, Akazawa C, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002; 53: 12-22.
Wolden SL, Chen WC, Kraus DH, Berry SL, Zelefsky MJ. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: up date of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006; 64: 57-62.
11. Xiao WW, Han F, Chen CY, Huang Y, Zhaoet C. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma Int J Radiat Oncol Biol Phys 2009; 74(4): 1070-6.
12. Xie SH, Yu ITS, Tse LA, Wai-kong Mang O, Yue L. Sex diference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983–2008: suggestion of a potential protective role of oestrogen. Eur J Cancer 2013; 49: 150-5.
13. Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, et al. Randomized phase 2 trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27: 242-9.
14. Chen L, Hu CS, Chen XZ, Hu GK, Cheng ZB, Sun Y, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012; 13: 163-71.
15. Xiao G, Cao Y, Qiu X, Wang W, Wang Y, et al. Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. BMC Cancer 2013; 13: 226.
16. Surveillance, Epidemiology, and End Results: SEER Cancer Statistics Review, 1975-2010. Available From: URL: http:// seer.cancer.gov/ csr/1975_2010
17. Kang MK, Heo D, Ahn YC, Moon SH, Wu HG, Heoet DS, et al. Role of chemotherapy in stage II nasopharyngeal carcinoma treated with curative radiotherapy. Cancer Res Treat 2015; 47: 871‐8.
18. Jin YN, Zhang WJ, Cai XY, Li MS, Lawrence WR, Wang SY, et al. The characteristics and survival outcomes in patients aged 70 years and older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy. Cancer Res Treat 2019; 51: 34-42.